Elahere

A Byers Institute Collaborative

A Byers Institute Collaborative

2

EGFR Inhibitors

4

“Ocular Adverse Events of Systemic Inhibitors of the Epidermal Growth Factor Receptor: Report of 5 Cases” Ophthalmology (2012)
“Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study”, Frontiers in Oncology (2020)
“Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review”, Supportive Care in Cancer (2012)
“Ocular Toxicities of Epidermal Growth Factor Receptor Inhibitors and Their Management”, Cancer Nursing (2007)

7

“Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database”, Ophthalmology (2021)
“OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS”, Retina (2019)
“New features in MEK retinopathy”, BMC Ophthalmology (2018)
“Ocular toxicity due to Trametinib and Dabrafenib”, BMC Ophthalmology (2017)
“Ocular toxicities of MEK inhibitors and other targeted therapies”, Annals of Oncology (2016)
“MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity”, Eye (2015)
“Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities”, Cancer Treatment Reviews (2013)

View Categories

Scroll to Top